Full article view2018-07-17T08:45:50+00:00

Precision’s Blandford in STAT First Opinion: The time for expansion of value-based drug reimbursement is now


Precision for Value’s Larry Blandford offers a new commentary in STAT First Opinion, insisting that payers and the pharmaceutical industry come together to develop a value-based drug reimbursement system. He suggests taking a page from the playbook developed for electronic prescribing as the key to moving forward.

Click here to read the complete commentary.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.